These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 29188782)

  • 1. Pharmacokinetic behavior of montelukast in indigenous healthy male volunteers.
    Fayyaz A; Khan JA; Ashraf MM; Akhter N; Aslam B; Khalid MF; Altaf S; Naseer RD; Akram M; Shah SMA; Khadam MW; Tahir IM
    Pak J Pharm Sci; 2017 Nov; 30(6(Supplementary)):2435-2439. PubMed ID: 29188782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioequivalence study of montelukast tablets in healthy Pakistani volunteers.
    Abbas M; Khan AM; Amin S; Riffat S; Ashraf M; Waheed N
    Pak J Pharm Sci; 2013 Mar; 26(2):255-9. PubMed ID: 23455193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of the bioequivalence of montelukast chewable tablets after a single oral administration using a validated LC-MS/MS method.
    Zaid AN; Abualhasan MN; Watson DG; Mousa A; Ghazal N; Bustami R
    Drug Des Devel Ther; 2015; 9():5315-21. PubMed ID: 26451086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the pharmacokinetics and tolerability of montelukast/levocetirizine administered as a fixed-dose combination and as separate tablets.
    Kim S; Ko JW; Kim JR
    Int J Clin Pharmacol Ther; 2018 Sep; 56(9):443-450. PubMed ID: 30021691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of clarithromycin and fluconazole on the pharmacokinetics of montelukast in human volunteers.
    Hegazy SK; Mabrouk MM; Elsisi AE; Mansour NO
    Eur J Clin Pharmacol; 2012 Sep; 68(9):1275-80. PubMed ID: 22392555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Montelukast pharmacokinetics in cystic fibrosis.
    Graff GR; Weber A; Wessler-Starman D; Smith AL
    J Pediatr; 2003 Jan; 142(1):53-6. PubMed ID: 12520255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females.
    Cheng H; Leff JA; Amin R; Gertz BJ; De Smet M; Noonan N; Rogers JD; Malbecq W; Meisner D; Somers G
    Pharm Res; 1996 Mar; 13(3):445-8. PubMed ID: 8692739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative pharmacokinetics of a montelukast/levocetirizine fixed-dose combination chewable tablet versus individual administration of montelukast and levocetirizine after a single oral administration in healthy Korean male subjects
.
    Moon SJ; Yu KS; Jung J; Kim YI; Kim MG
    Int J Clin Pharmacol Ther; 2020 Jun; 58(6):354-362. PubMed ID: 32271144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Montelukast dose selection in 6- to 14-year-olds: comparison of single-dose pharmacokinetics in children and adults.
    Knorr B; Larson P; Nguyen HH; Holland S; Reiss TF; Chervinsky P; Blake K; van Nispen CH; Noonan G; Freeman A; Haesen R; Michiels N; Rogers JD; Amin RD; Zhao J; Xu X; Seidenberg BC; Gertz BJ; Spielberg S
    J Clin Pharmacol; 1999 Aug; 39(8):786-93. PubMed ID: 10434229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clopidogrel but Not Prasugrel Significantly Inhibits the CYP2C8-Mediated Metabolism of Montelukast in Humans.
    Itkonen MK; Tornio A; Filppula AM; Neuvonen M; Neuvonen PJ; Niemi M; Backman JT
    Clin Pharmacol Ther; 2018 Sep; 104(3):495-504. PubMed ID: 29171020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers.
    Zhao JJ; Rogers JD; Holland SD; Larson P; Amin RD; Haesen R; Freeman A; Seiberling M; Merz M; Cheng H
    Biopharm Drug Dispos; 1997 Dec; 18(9):769-77. PubMed ID: 9429741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioequivalence studies for two different strengths of montelukast in healthy volunteers: 10 mg film-coated tablets and 5 mg chewable tablets.
    Pedroso P; Almeida S; Filipe A; Neves RI; Boudreault S; Jiménez C
    Drug Res (Stuttg); 2013 Sep; 63(9):477-83. PubMed ID: 23780502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A simple bioanalytical assay for determination of montelukast in human plasma: application to a pharmacokinetic study.
    Sripalakit P; Kongthong B; Saraphanchotiwitthaya A
    J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Jun; 869(1-2):38-44. PubMed ID: 18508416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pilot Study of Peak Plasma Concentration After High-Dose Oral Montelukast in Children With Acute Asthma Exacerbations.
    Arnold DH; Van Driest SL; Reiss TF; King JC; Akers WS
    J Clin Pharmacol; 2021 Mar; 61(3):360-367. PubMed ID: 32960980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of multiple doses of montelukast on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in humans.
    Kim KA; Park PW; Kim KR; Park JY
    Br J Clin Pharmacol; 2007 Mar; 63(3):339-45. PubMed ID: 16981900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does desloratadine alter the serum levels of montelukast when administered in a fixed-dose combination?
    Cingi C; Toros SZ; Ince I; Ertugay CK; Gurbuz MK; Cakli H; Erdogmus N; Karasulu E; Kaya E
    Laryngoscope; 2013 Nov; 123(11):2610-4. PubMed ID: 23918211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of citrus juice and SLCO2B1 genotype on the pharmacokinetics of montelukast.
    Mougey EB; Lang JE; Wen X; Lima JJ
    J Clin Pharmacol; 2011 May; 51(5):751-60. PubMed ID: 20974993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The targeted oral, once-daily phosphodiesterase 4 inhibitor roflumilast and the leukotriene receptor antagonist montelukast do not exhibit significant pharmacokinetic interactions.
    Böhmer GM; Nassr N; Wenger M; Hünnemeyer A; Lahu G; Templin S; Gleiter CH; Hermann R
    J Clin Pharmacol; 2009 Apr; 49(4):389-97. PubMed ID: 19318692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast.
    Karonen T; Filppula A; Laitila J; Niemi M; Neuvonen PJ; Backman JT
    Clin Pharmacol Ther; 2010 Aug; 88(2):223-30. PubMed ID: 20592724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of polymorphisms of the SLCO2B1 transporter gene on the pharmacokinetics of montelukast in humans.
    Kim KA; Lee HM; Joo HJ; Park IB; Park JY
    J Clin Pharmacol; 2013 Nov; 53(11):1186-93. PubMed ID: 23970434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.